Key result
GP IIb/IIIa inhibitor plus ticagrelor linked to ~51% higher major cardiovascular events risk vs ticagrelor alone in ACS.
Why the study?
The efficacy and safety of combined glycoprotein IIb/IIIa inhibitor and ticagrelor versus ticagrelor alone in patients with ACS required evaluation.
Does combined glycoprotein IIb/IIIa inhibitor and ticagrelor therapy improve major cardiovascular events in patients with acute coronary syndrome compared to ticagrelor alone?
Observational (n=13,264)
Yes
Does combined glycoprotein IIb/IIIa inhibitor and ticagrelor therapy improve major cardiovascular events in patients with acute coronary syndrome compared to ticagrelor alone?
In patients with acute coronary syndrome, the addition of a glycoprotein IIb/IIIa inhibitor to ticagrelor was associated with an increased risk of major cardiovascular events and bleeding without providing ischemic benefit.
Answers are grounded in this paper and cite their sources.
Cautions against routine GP IIb/IIIa addition to ticagrelor in ACS; leaves open confirmation in randomized trials.
This study was to compare the efficacy and safety of combined glycoprotein IIb/IIIa inhibitor (GPI) and ticagrelor versus ticagrelor in patients with acute coronary syndrome (ACS). An observational study was conducted using the Improving Care for Cardiovascular Disease in China-ACS project. Totally, 13,264 patients with ACS and received combination therapy or ticagrelor therapy were analyzed. The primary outcome was the composite of major cardiovascular events (MACE: all-cause mortality, myocardial infarction [MI], stent thrombosis, cardiogenic shock, and ischemic stroke), and secondary outcomes included all-cause mortality, MI, stent thrombosis, cardiogenic shock, and ischemic stroke. The multivariable adjusted analysis indicated that combination therapy was associated with an increased risk of major cardiovascular events (MACE) (P = 0.001), any bleeding (P<0.001), and major bleeding (P = 0.005). Moreover, the multivariable adjusted for propensity score-matched (PSM) analysis suggested that combination therapy produced additional risk of MACE (P = 0.014), any bleeding (P<0.001), and major bleeding (P = 0.005). Moreover, PSM analysis suggested that combination therapy was associated with greater risk of stent thrombosis (P = 0.012) and intracranial bleeding (P = 0.020). Combined GPI and ticagrelor therapies did not have any beneficial effects on MACE, stent thrombosis, intracranial bleeding, any bleeding, or major bleeding.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2021) conducted an observational in Acute coronary syndrome (n=13,264). Glycoprotein IIb/IIIa inhibitor (GPI) plus ticagrelor vs. Ticagrelor alone was evaluated on Major cardiovascular events (MACE: all-cause mortality, myocardial infarction, stent thrombosis, cardiogenic shock, and ischemic stroke) (OR 1.505, 95% CI 1.086-2.084, p=0.014). Combined glycoprotein IIb/IIIa inhibitor and ticagrelor therapy was associated with an increased risk of major cardiovascular events compared to ticagrelor alone in patients with acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: